Serial #85804016
DEAD

Serial Number

85804016

Owner

Synbias Pharma AG

Attorney

Thomas W. Brooke

Filing Date

Dec 17, 2012

Add to watchlist:

No watchlists yet
View on USPTO

Serial #85804016 Trademark

Serial Number: 85804016 • Registration: 4813223

Serial #85804016 is a trademark filed by Synbias Pharma AG on December 17, 2012. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Synbias Pharma AG (2 trademarks)

Pestalozzistr. 2
8200 Schaffhausen 8200 , CH

Entity Type: 99

Trademark Details

Filing Date

December 17, 2012

Registration Date

September 15, 2015

Published for Opposition

April 22, 2014

Cancellation Date

March 27, 2026

Goods & Services

Advertising, business management; business administration, business development; marketing services; office functions; regulatory submission management services, namely, assisting others in the preparation and deposit of regulatory documents in the field of veterinary and pharmaceutical preparations

Pharmaceutical and veterinary preparations for treating various types of cancers, diseases of the immunological system, namely, auto-immune diseases, and for prevention of organ rejection after transplantation; chemical preparations for pharmaceutical use, namely, for treating cancer and oncology diseases; chemical reagents for medical or veterinary use; pharmaceutical preparations for medical use for treating mainly cancer and oncology diseases; pharmaceutical preparations for use in chemotherapy; antibiotics

Scientific and technological services, namely, research and design in the field of chemicals, active pharmaceutical ingredients and pharmaceutical finished products and medicines; industrial analysis and research services in the field of chemicals, active pharmaceutical ingredients and pharmaceutical finished products and medicines; development of pharmaceutical preparations and medicines; research in the field of development and testing of pharmaceutical preparations

Legal services, namely, preparation and deposit for others of regulatory documents in the fields of veterinary and pharmaceutical preparations; patent search services for others

Industrial chemicals; active chemical ingredients for use in the manufacture of chemotherapeutic medicines; active chemical ingredients for use in the manufacture of medicines for treating a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas, breast and ovarian cancer, gastric cancer, lung cancer and lymphomas, acute myeloid leukemia, bladder cancer, metastatic breast cancer, metastatic breast cancer, acute myeloid leukemia, and non-Hodgkin's lymphoblastic leukaemia, breast cancer and non-small cell lung cancer, ovarian cancer and lung cancer, colon cancer, in particular, in combination with other chemotherapy, hairy cell leukemia (HCL) and multiple sclerosis, hematological malignancies, T-cell acute lymphoblastic leukemia, relapsed or refractory acute lymphoblastic leukaemia (ALL) in children after at least two other types of treatment have failed, acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML), myelodysplastic syndromes, a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML), immunosuppressant to prevent rejection in organ transplantation, it is especially useful in kidney transplants, to prevent rejection of organ transplants and treatment of renal cell cancer and other tumors, aggressive metastatic or locally advanced breast cancer, multiple myeloma, hematological disorders known as myelodysplastic syndromes (MDS), chronic lymphocytic leukemia, lymphomas and sarcoma, hormone-regractory prostate cancer, lymphoma and multiple myeloma, diseases of the immunological system, namely, auto-immune diseases, and prevention of organ rejection after transplantation; chemical preparations for use as intermediates for manufacture of finished active pharmaceutical ingredients for treating a wide range of cancers, diseases of the immunological system, namely, auto-immune diseases, and prevention of organ rejection after transplantation

Filing History

CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Mar 27, 2026 CAEX
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Sep 15, 2024 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Dec 15, 2021 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Dec 15, 2021 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 14, 2021 APRE
TEAS SECTION 8 & 15 RECEIVED
Sep 14, 2021 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Sep 15, 2020 REM1
REGISTERED-PRINCIPAL REGISTER
Sep 15, 2015 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Aug 11, 2015 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Aug 10, 2015 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jul 17, 2015 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 14, 2015 AITU
USE AMENDMENT FILED
Jun 15, 2015 IUAF
TEAS STATEMENT OF USE RECEIVED
Jun 15, 2015 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 9, 2014 EXRA
SOU EXTENSION 1 GRANTED
Dec 5, 2014 EX1G
SOU EXTENSION 1 FILED
Dec 5, 2014 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 5, 2014 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 17, 2014 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 22, 2014 NPUB
PUBLISHED FOR OPPOSITION
Apr 22, 2014 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 2, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 15, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 4, 2014 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 4, 2014 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 4, 2014 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 4, 2014 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 4, 2014 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 5, 2013 GNFN
FINAL REFUSAL E-MAILED
Sep 5, 2013 GNFR
FINAL REFUSAL WRITTEN
Sep 5, 2013 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 13, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 12, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 12, 2013 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Apr 2, 2013 GPRN
PRIORITY ACTION E-MAILED
Apr 2, 2013 GPRA
PRIORITY ACTION WRITTEN
Apr 2, 2013 CPRA
ASSIGNED TO EXAMINER
Apr 1, 2013 DOCK
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 9, 2013 CHAN
ASSIGNED TO LIE
Feb 5, 2013 ALIE
PAPER RECEIVED
Jan 31, 2013 MAIL
NOTICE OF DESIGN SEARCH CODE MAILED
Jan 5, 2013 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 4, 2013 NWOS
NEW APPLICATION ENTERED
Dec 20, 2012 NWAP